Adverum Biotechnologies (Nasdaq: ADVM) is a clinical-stage gene therapy company targeting unmet medical needs for serious ocular and rare diseases. Adverum is evaluating its novel gene therapy candidate, ADVM-022, as a one-time, intravitreal injection for the treatment of its lead indication, wet age-related macular degeneration.

Biotechnology

Adverum Biotech

Laurent Fischer

Jason L. Mitchell

Joanna D.

Adam Turpcu

Rabia Gurses Ozden

Romuald Corbau

R. Andrew Ramelmeier

Bill Tan

Linda Rubinstein

Star Seyedkazemi

Dena House

John Rakow

Heikki Jouttijärvi

Kishor Peter Soparkar

Carla Fiankan

Corporate Affairs

Leadership Team

Scientific Team

Clinical Operations

Operations Team

Engineering and IT

Quality and Regulatory Affairs Team

Finance and Accounting Team

Teams at Adverum Biotech